PKY.ASX Quarterly Report Highlights
Key points
- Chipforge Acquisition Completed
- MOU with Inturai Ventures Corp for drone-swarm command and control
- TrialKey generated $30,000 in revenue
- Cash balance of $3.41M as at 30 June 2026
Full summary
Pathkey.AI Ltd (ASX: PKY) has released its quarterly activities and cash flow report for the period ended 30 June 2026. The company completed the acquisition of Chipforge, an AI-driven semiconductor hardware design platform, and has integrated the team and expanded capabilities in Singapore and Australia. Chipforge has signed a memorandum of understanding with Inturai Ventures Corp to build drone-swarm command and control on edge silicon. The company also commercialized its TrialKey platform with increasing revenue generation and platform development. TrialKey generated $30,000 in revenue during the quarter, including $25,000 from Imunexus Therapeutics Limited and $5,000 from Armstrong Clinical. The company held $3.41 million in cash as at 30 June 2026, including $870,000 from option exercises. Pathkey.AI continues to participate in R&D Tax Incentive Programs.
Guidance
Cash balance of $3.41M as at 30 June 2026
Outlook
Pathkey.AI expects continued growth in revenue and platform development for both Chipforge and TrialKey.
Summary generated by a large language model. Please interpret with care.